L1CAM expression in endometrial carcinomas: An ENITEC collaboration study

Louis J.M. Van Der Putten; Nicole C.M. Visser; Koen Van De Vijver; Maria Santacana; Peter Bronsert; Johan Bulten; Marc Hirschfeld; Eva Colas; Antonio Gil-Moreno; Angel Garcia; Gemma Mancebo; Fransesc Alameda; Jone Trovik; Reidun K. Kopperud; Jutta Huvila; Stefanie Schrauwen; Martin Koskas; Francine Walker; Vit Weinberger; Lubos Minar; Eva Jandakova; Marc P.L.M. Snijders; Saskia Van Den Berg-Van Erp; Xavier Matias-Guiu; Helga B. Salvesen; Frederic Amant; Leon F.A.G. Massuger; Johanna M.A. Pijnenborg

doi:https://doi.org/10.1038/bjc.2016.235

L1CAM expression in endometrial carcinomas: An ENITEC collaboration study

Louis J.M. Van Der Putten, Nicole C.M. Visser, Koen Van De Vijver, Maria Santacana, Peter Bronsert, Johan Bulten, Marc Hirschfeld, Eva Colas, Antonio Gil-Moreno, Angel Garcia, Gemma Mancebo, Fransesc Alameda, Jone Trovik, Reidun K. Kopperud, Jutta Huvila, Stefanie Schrauwen, Martin Koskas, Francine Walker, Vit Weinberger, Lubos MinarEva Jandakova, Marc P.L.M. Snijders, Saskia Van Den Berg-Van Erp, Xavier Matias-Guiu, Helga B. Salvesen, Frederic Amant, Leon F.A.G. Massuger, Johanna M.A. Pijnenborg

Research output: Contribution to journal › Article › Research › peer-review

70 Citations (Scopus)

Abstract

© 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.

Original language	English
Pages (from-to)	716-724
Journal	British Journal of Cancer
Volume	115
Issue number	6
DOIs	https://doi.org/10.1038/bjc.2016.235
Publication status	Published - 6 Sept 2016

Keywords

L1CAM
endometrial cancer
endometrioid
immunohistochemistry
non-endometrioid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1038/bjc.2016.235

https://ddd.uab.cat/record/185951

Cite this

Van Der Putten, L. J. M., Visser, N. C. M., Van De Vijver, K., Santacana, M., Bronsert, P., Bulten, J., Hirschfeld, M., Colas, E., Gil-Moreno, A., Garcia, A., Mancebo, G., Alameda, F., Trovik, J., Kopperud, R. K., Huvila, J., Schrauwen, S., Koskas, M., Walker, F., Weinberger, V., ... Pijnenborg, J. M. A. (2016). L1CAM expression in endometrial carcinomas: An ENITEC collaboration study. British Journal of Cancer, 115(6), 716-724. https://doi.org/10.1038/bjc.2016.235

@article{daa0b16165b141b7aa23bcb3c3488791,

title = "L1CAM expression in endometrial carcinomas: An ENITEC collaboration study",

abstract = "{\textcopyright} 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.",

keywords = "L1CAM, endometrial cancer, endometrioid, immunohistochemistry, non-endometrioid",

author = "{Van Der Putten}, {Louis J.M.} and Visser, {Nicole C.M.} and {Van De Vijver}, Koen and Maria Santacana and Peter Bronsert and Johan Bulten and Marc Hirschfeld and Eva Colas and Antonio Gil-Moreno and Angel Garcia and Gemma Mancebo and Fransesc Alameda and Jone Trovik and Kopperud, {Reidun K.} and Jutta Huvila and Stefanie Schrauwen and Martin Koskas and Francine Walker and Vit Weinberger and Lubos Minar and Eva Jandakova and Snijders, {Marc P.L.M.} and {Van Den Berg-Van Erp}, Saskia and Xavier Matias-Guiu and Salvesen, {Helga B.} and Frederic Amant and Massuger, {Leon F.A.G.} and Pijnenborg, {Johanna M.A.}",

year = "2016",

month = sep,

day = "6",

doi = "https://doi.org/10.1038/bjc.2016.235",

language = "English",

volume = "115",

pages = "716--724",

number = "6",

}

Van Der Putten, LJM, Visser, NCM, Van De Vijver, K, Santacana, M, Bronsert, P, Bulten, J, Hirschfeld, M, Colas, E, Gil-Moreno, A, Garcia, A, Mancebo, G, Alameda, F, Trovik, J, Kopperud, RK, Huvila, J, Schrauwen, S, Koskas, M, Walker, F, Weinberger, V, Minar, L, Jandakova, E, Snijders, MPLM, Van Den Berg-Van Erp, S, Matias-Guiu, X, Salvesen, HB, Amant, F, Massuger, LFAG & Pijnenborg, JMA 2016, 'L1CAM expression in endometrial carcinomas: An ENITEC collaboration study', British Journal of Cancer, vol. 115, no. 6, pp. 716-724. https://doi.org/10.1038/bjc.2016.235

TY - JOUR

T1 - L1CAM expression in endometrial carcinomas: An ENITEC collaboration study

AU - Van Der Putten, Louis J.M.

AU - Visser, Nicole C.M.

AU - Van De Vijver, Koen

AU - Santacana, Maria

AU - Bronsert, Peter

AU - Bulten, Johan

AU - Hirschfeld, Marc

AU - Colas, Eva

AU - Gil-Moreno, Antonio

AU - Garcia, Angel

AU - Mancebo, Gemma

AU - Alameda, Fransesc

AU - Trovik, Jone

AU - Kopperud, Reidun K.

AU - Huvila, Jutta

AU - Schrauwen, Stefanie

AU - Koskas, Martin

AU - Walker, Francine

AU - Weinberger, Vit

AU - Minar, Lubos

AU - Jandakova, Eva

AU - Snijders, Marc P.L.M.

AU - Van Den Berg-Van Erp, Saskia

AU - Matias-Guiu, Xavier

AU - Salvesen, Helga B.

AU - Amant, Frederic

AU - Massuger, Leon F.A.G.

AU - Pijnenborg, Johanna M.A.

PY - 2016/9/6

Y1 - 2016/9/6

N2 - © 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.

AB - © 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.

KW - L1CAM

KW - endometrial cancer

KW - endometrioid

KW - immunohistochemistry

KW - non-endometrioid

U2 - https://doi.org/10.1038/bjc.2016.235

DO - https://doi.org/10.1038/bjc.2016.235

M3 - Article

VL - 115

SP - 716

EP - 724

IS - 6

ER -

L1CAM expression in endometrial carcinomas: An ENITEC collaboration study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this